The following video is part of our "Motley Fool Conversations" series, in which David Williamson, health-care editor and analyst, and Brendan Byrnes, industrials editor and analyst, discuss topics around the investing world.
In today's edition, David and Brendan discuss some of the worst health-care stocks of 2011. These stocks fit relatively neatly into three categories: failure to launch, trial troubles, and home health-care scare. This video focuses on failure to launch -- i.e., companies whose drug candidates made it through the rigorous approval process only to be met with a lukewarm (or downright cold) commercial reception. They also discuss which of the downtrodden stocks are likely to get sales rolling in 2012.
David Williamson owns shares of Dendreon. Brendan Byrnes owns no shares of the companies mentioned here. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Avanir Pharmaceuticals Inc. Stock Leaped 14% in December
Avanir Pharmaceuticals shares rocket higher after agreeing to be purchased by a major overseas pharmaceutical company.
3 Traits of the Best Healthcare Stocks in 2014
The best healthcare stocks in 2014 saw their shares gain as much as 400% because they exhibited at least one of the following three key traits.
Why Avanir Pharmaceuticals Inc. Stock Rocketed Higher
Avanir Pharmaceuticals shares soar after the company agrees to be bought out. Find out whether or not the price paid was fair for shareholders and whether the deal makes sense.